88920-24-5

Basic information

• Product Name: (4-Methoxybenzyloxy)acetic acid
• Synonyms: (4-METHOXYBENZYLOXY)ACETIC ACID;2-((4-Methoxybenzyl)oxy)acetic acid
• CAS NO: 88920-24-5
• Molecular Formula: C₁₀H₁₂O₄
• Molecular Weight: 196.2
• Mol File: 88920-24-5.mol
• Article Data: 19

Chemical Properties

• Melting Point: 50.8-51.8 °C(Solv: ethyl ether (60-29-7); ligroine (8032-32-4))
• Boiling Point: 367.4 °C at 760 mmHg
• Flash Point: 146.9 °C
• Appearance: /
• Density: 1.198 g/cm₃
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.528
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 3.40±0.10(Predicted)
• CAS DataBase Reference: (4-Methoxybenzyloxy)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (4-Methoxybenzyloxy)acetic acid(88920-24-5)
• EPA Substance Registry System: (4-Methoxybenzyloxy)acetic acid(88920-24-5)

Safety Data

• Hazardous Substances Data: 88920-24-5(Hazardous Substances Data)

Usage

General Description

(4-Methoxybenzyloxy)acetic acid is a chemical compound that consists of a benzene ring with a methoxy group attached to it, along with a carboxylic acid group. It is often used as an intermediate in organic synthesis, particularly in the production of pharmaceuticals and agrochemicals. (4-Methoxybenzyloxy)acetic acid may have potential applications in the development of new drugs due to its ability to act as a building block for more complex molecules. Additionally, it has been studied for its potential biological activity and its role in various chemical reactions. Overall, (4-Methoxybenzyloxy)acetic acid represents an important intermediate in organic chemistry with potential implications for medicinal and agricultural purposes.

InChI:InChI=1/C10H12O4/c1-13-9-4-2-8(3-5-9)6-14-7-10(11)12/h2-5H,6-7H2,1H3,(H,11,12)

Upstream product

• 38233-96-4 ethyl 2-hydroxyacetate sodium salt 
• 824-94-2 p-methoxybenzyl chloride 
• 79-08-3 bromoacetic acid 
• 105-13-5 4-Methoxybenzyl alcohol 
• 79-11-8 chloroacetic acid 
• 105-36-2 ethyl bromoacetate 
• 79-14-1 glycolic Acid 
• 623-50-7 ethyl 2-hydroxyacetate 
• 89238-99-3 O-(4-methoxybenzyl)-trichloroacetimidate 
• 123-11-5 4-methoxy-benzaldehyde 

Downstream Products

• 142611-69-6 (3R)-(Z)-1-(Dimethylphenylsilyl)-1-buten-3-yl ((4-methoxybenzyl)oxy)acetate 
• 88920-32-5 p-methoxybenzyloxymethyl p-methoxybenzyloxyacetate 
• 318514-55-5 C₁₅H₂₀O₅ 
• 165817-35-6 (4-Methoxy-benzyloxy)-acetic acid (S)-1-((S)-1-benzyloxy-ethyl)-allyl ester 
• 51759-07-0 (4-methoxybenzyloxy)acetic acid methyl ester 
• 220802-94-8 (4-Methoxy-benzyloxy)-acetic acid (1S,5S,6S)-6-(tert-butyl-dimethyl-silanyloxy)-5-(3-methoxy-benzyloxy)-cyclohex-2-enyl ester 
• 120370-90-3 8,13-epoxy-7β-<(4-methoxybenzyloxy)acetoxy>-1α,6β,9α-trihydroxylabd-14-en-11-one 
• 120370-81-2 1α,7β-bis<(4-methoxybenzyloxy)acetoxy>-6β,9α-dihydroxy-8,13-epoxylabd-14-en-11-one 
• 120370-89-0 7β-acetoxy-6β,9α-dihydroxy-8,13-epoxy-1α-<(4-methoxybenzyloxy)acetoxy>labd-14-en-11-one 
• 220248-25-9 6β,9α-dihydroxy-8,13-epoxy-7β-<(4-methoxybenzyloxy)acetoxy>-1α-tertbutyldimethylsilyloxylabd-14-en-11-one 
• 267642-31-9 (E)-4-(phenylmethoxy)but-2-enyl 2-[(4-methoxyphenyl)methoxy]acetate 
• 287400-43-5 (4-methoxy-benzyloxy)-acetic acid 2-(tert-butyl-diphenyl-silanyloxymethyl)-4-[(4-methoxy-benzyloxy)-acetoxy]-5-methyl-3,4-dihydro-2H-pyran-3-yl ester 
• 265666-18-0 (1S,2'S,4'R,6'R)-[6'-{2-hydroxy-1-[2-(4-methoxybenzyloxy)-acetylamino]-ethyl}-4'-(triisopropylsilanyloxy)-tetrahydropyran-2'-yl]-acetic acid ethyl ester 
• 306976-03-4 (4-Methoxy-benzyloxy)-acetic acid (E)-1-(1-ethoxy-vinyl)-hex-2-enyl ester 

Relevant articles and documents

Synthesis of a new lactenediyne scaffold equipped with three handles

A new lactenediyne scaffold endowed with three attachment points for substituents (handles) was synthesized. This scaffold was designed in order to be used to prepare libraries of compounds possessing a tethered nucleophile, an activating substituent, and DNA-complexing substructures.

An RCM-Based Total Synthesis of the Antibiotic Disciformycin B

The total synthesis of the potent new antibiotic disciformycin B (2) is described, which shows significant activity against methicillin- and vancomycin-resistant Staphylococcus aureus (MRSA/VRSA) strains. The synthetic route is based on macrocyclization o

Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) to Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo

Nucleotide-binding oligomerization domain-like receptors (NLRs) are intracellular sensors of pathogen-Associated molecular patterns (PAMPs) and damage-Associated molecular patterns (DAMPs). Previously, we reported nucleotide-binding oligomerization domain-containing protein 1 (NOD1) antagonists (11, 12) and a NOD2 antagonist (9) that sensitized docetaxel (DTX) or paclitaxel (PTX) treatment for breast or lung cancer. In this article, we describe for the first time a 1,4-benzodiazepine-2,5-dione (BZD) derivative (26bh) that acts as a dual NOD1/NOD2 antagonist and inhibits both nuclear factor B (NF-B) and mitogen-Activated protein kinase (MAPK) inflammatory signaling, thereby sensitizing PTX to suppress Lewis lung carcinoma (LLC) growth. After investigation of the compound's cytotoxicity, a systematic structure-Activity relationship (SAR) was completed and revealed several key factors that were necessary to maintain antagonistic ability. This study establishes the possibility for using adjuvant treatment to combat cancer by antagonizing both NOD1 and NOD2 signaling.